The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- N/A
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM
- Status
- UNKNOWN
- Phase
- PHASE1
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Status
- UNKNOWN
- Phase
- NA
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
- Status
- TERMINATED
- Phase
- NA
COVID-19 Infection and Multiple Myeloma
- Status
- COMPLETED
- Phase
- N/A
Virtual Exercise for Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Personalized Autologous Transplant for Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
- Status
- WITHDRAWN
- Phase
- PHASE1
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- NA